Health
Goldman gave clients a list of stocks that may surge if a coronavirus vaccine is approved – CNBC
With several Covid-19 vaccines in Phase 3 trials, Goldman Sachs is preparing its clients for a rebound in certain stocks.
(This story is only for CNBC Pro subscribers)
With several Covid-19 vaccines in Phase 3 trials and preliminary data due as soon as later this month, Goldman Sachs is preparing its clients for a rebound in certain stocks and recommending tweaks to client portfolios.
It grouped a list of several U.S. equities into four buckets.
The first bucket includes stocks that have sold off in 2020 but should bounce back as people “‘return to normal.'” The second bucket is comprised of equities that appear…
Continue Reading